{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:58:47Z","timestamp":1782237527838,"version":"3.54.5"},"reference-count":35,"publisher":"Korean Continence Society","issue":"3","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["einj.org"],"crossmark-restriction":true},"short-container-title":["Int Neurourol J"],"published-print":{"date-parts":[[2025,9,30]]},"abstract":"<jats:p>Purpose: Low bladder compliance (BC) poses a significant clinical challenge. Nevertheless, studies exploring pharmacological mechanisms to improve BC remain limited. We investigated the efficacy of a \u03b23-adrenoceptor agonist, mirabegron, on BC in comparison with anticholinergics.Methods: This prospective single-arm paired comparison trial included 14 patients with low BC (\u226420 mL\/cm H2O) despite anticholinergics treatment. After a 2-week anticholinergics-washout period, patients were treated with mirabegron for 8 weeks and then returned to 8 weeks of anticholinergics. Major treatment effect was assessed with urodynamic studies performed at baseline, 8 weeks after mirabegron treatment, and 8 weeks after consecutive anticholinergics treatment (McNemar test, Paired t-test; mean [95% confidence intervals]).Results: Following mirabegron, 71.43% of patients exhibited a BC of &gt;20 mL\/cm H\u2082O, compared to 54.55% after switching back to anticholinergics (P=0.317). BC improved significantly from 12.02 (9.52\u201314.52) to 39.67 (21.60\u201357.73) mL\/cm H2O after mirabegron treatment (P=0.007), but subsequently declined to 20.94 (15.78\u201326.10) mL\/cm H\u2082O after reintroduction of anticholinergics (P=0.075). Maximum cystometric capacity increased from 352.21 (282.78\u2013421.65) to 442.71 (348.95\u2013536.48) mL after mirabegron (P=0.091), but decreased to 402.00 (315.92\u2013488.08) mL after returning to anticholinergics (P=0.218). Notably, detrusor pressure at end-filling decreased significantly with mirabegron, from 30.50 (25.61\u201335.39) to 14.43 (10.79\u201318.06) cm H2O (P&lt;0.001), while increasing to 20.36 (16.26\u201324.46) cm H2O after returning to anticholinergics (P=0.056).Conclusions: A \u03b23-adrenoceptor agonist, mirabegron, was more effective than anticholinergics in improving BC. Among the two components of improved BC\u2014increased bladder volume and reduced detrusor filling pressure\u2014the \u03b23-adrenoceptor agonist showed a more pronounced effect on lowering detrusor filling pressure, compared to anticholinergics. These findings suggest that \u03b23-adrenoceptor agonists might play an important role in reducing the tension of the bladder wall by controlling detrusor muscle tone, and this may be an important target for future research.<\/jats:p>","DOI":"10.5213\/inj.2550050.025","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T06:19:01Z","timestamp":1758867541000},"page":"197-206","update-policy":"https:\/\/doi.org\/10.5213\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Prospective Paired Comparison Trial of Mirabegron and Anticholinergics in Patients With Low Bladder Compliance"],"prefix":"10.5213","volume":"29","author":[{"given":"Hee Seo","family":"Son","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9056-7072","authenticated-orcid":true,"given":"Jang Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3166","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.026"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-5895-1_5"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)64226-7"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)36650-8"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.036"},{"key":"ref6","first-page":"1173","volume-title":"Selective beta(3)-adrenoceptor agonists for the treatment of overactive bladder","author":"Andersson","year":"2013"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16142"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)38389-1"},{"key":"ref9","volume-title":"","author":"Derendorf","year":"2019"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.09.010"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23124"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23397"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.11.040"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.030"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.02.057"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13598"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/003655999750042178"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000282294"},{"key":"ref19","first-page":"664","volume-title":"Protective effect of a beta3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia","author":"Sawada","year":"2013"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01937"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21223"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/apha.12373"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.2005.05455.x"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.04.082"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000069722.35137.e0"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-014-0808-9"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(01)05549-0"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2016.06.002"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.04.039"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25127"},{"key":"ref31","first-page":"1165","volume-title":"Effects of mirabegron, a novel beta3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin","author":"Aizawa","year":"2012"},{"key":"ref32","first-page":"449","volume-title":"Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors","author":"Michel","year":"2008"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.01.010"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/nau.70043"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.12.014"}],"container-title":["International Neurourology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/einj.org\/upload\/pdf\/inj-2550050-025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/einj.org\/journal\/view.php?doi=10.5213\/inj.2550050.025","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/einj.org\/upload\/pdf\/inj-2550050-025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T23:02:45Z","timestamp":1759100565000},"score":1,"resource":{"primary":{"URL":"http:\/\/einj.org\/journal\/view.php?doi=10.5213\/inj.2550050.025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.5213\/inj.2550050.025","relation":{},"ISSN":["2093-6931"],"issn-type":[{"value":"2093-6931","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"2025-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}